Lawsuit Details - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of AstraZeneca PLC securities between February 23, 2022, and December 17, 2024 [1] - The lawsuit alleges that AstraZeneca made materially false and/or misleading statements and/or failed to disclose key information during the Class Period [3] - The allegations include AstraZeneca engaging in insurance fraud in China, leading to heightened legal exposure and the detention of the AstraZeneca China President by Chinese authorities [3] - The lawsuit claims that AstraZeneca understated its legal risks and that the revelations could materially harm its business activities in China [3] - Investors allegedly suffered damages when the true details entered the market [3] Legal Process - A class action lawsuit has already been filed, and potential lead plaintiffs must move the Court no later than February 21, 2025 [1][2] - No class has been certified yet, and investors are not represented by counsel unless they retain one [4] - Investors may select their own counsel or remain absent class members without taking action [4] - The ability to share in any potential future recovery is not dependent upon serving as lead plaintiff [4] Compensation and Fees - Investors who purchased AstraZeneca securities during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement [7] Rosen Law Firm Background - Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, representing investors globally [8] - The firm achieved the largest ever securities class action settlement against a Chinese company at the time [8] - Ranked No 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and consistently ranked in the top 4 since 2013 [8] - Recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [8] - Founding partner Laurence Rosen was named a Titan of Plaintiffs' Bar by Law360 in 2020 [8] Contact Information - Investors can join the AstraZeneca class action by visiting the Rosen Law Firm website or contacting Phillip Kim, Esq toll-free at 866-767-3653 or via email [2][9][12] - Updates on the case can be followed on LinkedIn, Twitter, and Facebook [10]

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=118944&from=4 CLASS PERIOD: February 23, 2022 t ...

NEW ORLEANS, Dec. 27, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against AstraZeneca PLC (the "Company") (NasdaqGS: AZN), if they purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"). This action is pending in the United States Distric ...

Investigation Overview - Pomerantz LLP is investigating claims on behalf of AstraZeneca investors regarding potential securities fraud or unlawful business practices [2][3] - The investigation involves AstraZeneca and certain officers and/or directors [3] Market Impact - AstraZeneca's ADR price fell $5 16 per ADR or 7 22% to close at $66 27 per ADR on November 5 2024 [5] Expanded Investigation - The fraud investigation into AstraZeneca has expanded to include several Chinese government agencies implicating dozens of senior executives at the company [6] Firm Background - Pomerantz LLP is a premier firm in corporate securities and antitrust class litigation with offices in multiple global cities [4] - The firm has a history of recovering multimillion-dollar damages awards for class members [4]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

AstraZeneca (AZN) and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application (MAA) for their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd).The MAA sought approval of Dato-DXd for treating adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase III study.The companies decided to withdraw the MAA for Dato-DXd in nonsquamous NSCLC following feedback ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AstraZeneca PLC ("AstraZeneca PLC" or the "Company") (NASDAQ: AZN) investors of a class action representing investors that bought securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"). AstraZeneca PLC investors have until February 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact ...

AstraZeneca (AZN) announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC).The eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 (L858R) substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDA approved this combination in September for a similar indication.The nod i ...

U.K.-based pharmaceutical giant AstraZeneca (AZN 1.41%) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as well as several other top executives -- were arrested following fraud-related investigations by the authorities. AstraZeneca expects a sales hit in China, one of its most important international markets.The drugmaker's issues in China have weighed heavily on its performance of late, and its stock is down by ab ...

The most recent trading session ended with Astrazeneca (AZN) standing at $65.35, reflecting a +1.41% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 1.09%. Meanwhile, the Dow experienced a rise of 1.18%, and the technology-dominated Nasdaq saw an increase of 1.03%.Heading into today, shares of the pharmaceutical had gained 0.28% over the past month, outpacing the Medical sector's loss of 2.76% and the S&P 500's loss of 0.71% in that time.Analysts and investors ...